Skip to main
RXST

RxSight (RXST) Stock Forecast & Price Target

RxSight (RXST) Analyst Ratings

Based on 8 analyst ratings
Hold
Strong Buy 13%
Buy 0%
Hold 63%
Sell 25%
Strong Sell 0%

Bulls say

RxSight is a promising biotechnology company with a unique product offering that has the potential to drive significant growth in the future. The company's collaboration with ALC and their positive recent earnings report indicate strong potential for increased utilization and market share in the premium category. Additionally, the company's solid financials and promising pipeline for light adjustable lenses make it a strong investment option.

Bears say

RxSight is facing various risks that may impede the company's growth potential, including lackluster adoption due to the additional capital equipment required, challenges in commercial execution, intensifying competition in the intraocular lens market, and the possibility of a dilutive financing round. The company's recently announced collaboration with Alcon may showcase its technology's value, but overall, disappointing underlying sales in the second quarter and lowered revenue guidance for 2026 suggest a weakening performance. While RxSight did report better-than-expected gross margin and in-line revenue for the quarter, its operating expenses were higher than anticipated, and the company still faces challenges in utilization and margin contraction. Based on these factors, it may be prudent to maintain a negative outlook on RxSight's stock, with potential upside drivers including faster LDD installed base growth, higher utilization, and improved LAL volumes and margins.

RxSight (RXST) has been analyzed by 8 analysts, with a consensus rating of Hold. 13% of analysts recommend a Strong Buy, 0% recommend Buy, 63% suggest Holding, 25% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of RxSight and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About RxSight (RXST) Forecast

Analysts have given RxSight (RXST) a Hold based on their latest research and market trends.

According to 8 analysts, RxSight (RXST) has a Hold consensus rating as of Jul 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.19, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.19, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

RxSight (RXST)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.